OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Social care data in the UK; current landscape, challenges, and future recommendations	27
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	22
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	20
Adherence to augmentation therapy for the treatment of major depressive disorder	17
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	16
How to create value with constrained budgets in oncological care? A narrative review	15
Indication-based pricing of the pharmaceuticals in Croatia: case-study	14
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	14
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	13
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	13
The role of insurance policies in the drug pricing landscape	13
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	12
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review	12
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	12
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	11
A methodological guide for implementing and interpreting results of probabilistic analysis	10
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	10
The impact of under-investment on health in Southern and Central Eastern European Countries	10
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	10
Burden of disease and costs of infections associated with cardiac implantable electronic devices	10
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	9
Access to medicines, care, and services for multiple sclerosis patients in central and eastern European countries: a comparative analysis	9
Consumption of antidepressants and economic austerity in Brazil	9
An update on the economic burden of type 2 diabetes mellitus in China	9
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	8

Valuing quality of life for economic evaluations in cancer: navigating multiple methods	8
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	8
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	8
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	8
The impact of bone turnover marker on medication adherence and the health economics-related consequences	8
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	8
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	7
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	7
Systematic reviews of machine learning in healthcare: a literature review	7
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	7
Digital measures in epilepsy in low-resourced environments	7
Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation	7
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	6
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	6
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma	6
How relevant is the BMI for cost-of-illness studies in the 21st century?	6
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	6
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	6
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	6
Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study	6
Burden of disease of chronic pain in Ecuador	6
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	6
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	6
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	6
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	6
Estimation of the economic burden of atrial fibrillation-related stroke in Greece	5
Developing the Lebanese health economic evaluation guideline	5
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	5
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	5
Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing	5
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies	5
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	5
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	5
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	5
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	5
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data	5
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	5
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy	5
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	5
Bridging the gap: enhancing medication adherence through research and innovation	5
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain	4
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	4
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	4
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	4
The hidden burden of atopic dermatitis in central and Eastern European countries	4
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	4
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4

The Lebanese health economic evaluation guideline	4
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	4
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	4
Economic benefits of global Collaborative Health technology	4
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	4
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	4
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	4
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	4
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	4
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	4
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	4
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)	4
Perspectives in prospective comparative economic evaluations: a systematic review	3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece	3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	3
Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia	3
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	3
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	3
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	3
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	3
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	3
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	3
Imputing missing patient-level data and propensity score matching in cost-effectiveness analysis in Crohn's disease	3
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China	3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population	3
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model	3
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	3
Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience	3
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review	3
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	3
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	3
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer	3
Implementing a Managed Entry Agreement Framework in Cyprus	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
Burden of disease of chronic pain in Colombia	3
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare	3
What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system	3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	3
Public value judgments about the criteria for reimbursement of medicines in South Korea	3
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	3
The short-term impact of copayment reductions for government subsidised medicines in Australia	3
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	3
Correction	3
The economic impact of pharmacist intervention during pandemics	3
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	3
Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand	3